{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:14:06Z","timestamp":1794377646848,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["17\/25284-2"],"award-info":[{"award-number":["17\/25284-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/25290-2"],"award-info":[{"award-number":["2017\/25290-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["22\/04368"],"award-info":[{"award-number":["22\/04368"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["15\/26580-9"],"award-info":[{"award-number":["15\/26580-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["22\/15913-0"],"award-info":[{"award-number":["22\/15913-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["18\/25555-9"],"award-info":[{"award-number":["18\/25555-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310497\/2021-3"],"award-info":[{"award-number":["310497\/2021-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["401811\/2024-7"],"award-info":[{"award-number":["401811\/2024-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omton.2025.200942","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T19:15:45Z","timestamp":1738091745000},"page":"200942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade"],"prefix":"10.1016","volume":"33","author":[{"given":"Ana Carolina M.","family":"Domingues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia B.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayara G.","family":"Tessarollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Lepique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Sharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleigha","family":"Lawless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madak","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell W.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4113-9450","authenticated-orcid":false,"given":"Bryan E.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.200942_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200942_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T\u00a0cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.200942_bib3","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","article-title":"The state of cell and gene therapy in 2023","volume":"31","author":"Chancellor","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.200942_bib4","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray Bsc","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omton.2025.200942_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576658","article-title":"Combined p14ARF and Interferon-\u03b2 Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation","volume":"11","author":"Cerqueira","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.200942_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddiscovery.2017.17","article-title":"Reestablishment of p53\/Arf and interferon-\u03b2 pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death","volume":"3","author":"Hunger","year":"2017","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.omton.2025.200942_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-17775-y","article-title":"Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy","volume":"12","author":"Medrano","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200942_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1089\/dna.2022.0115","article-title":"Induction of Immune-Stimulating Factors and Oncolysis Upon p14ARF Gene Transfer in Melanoma Cell Lines","volume":"42","author":"Mendon\u00e7a","year":"2023","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.omton.2025.200942_bib9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s43018-024-00796-z","article-title":"p53 at the crossroads of tumor immunity","volume":"5","author":"Efe","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.omton.2025.200942_bib10","doi-asserted-by":"crossref","first-page":"32275","DOI":"10.1074\/jbc.M313830200","article-title":"Different Requirements for the Cytostatic and Apoptotic Effects of Type I Interferons: INDUCTION OF APOPTOSIS REQUIRES ARF BUT NOT p53 IN OSTEOSARCOMA CELL LINES","volume":"279","author":"Sandoval","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omton.2025.200942_bib11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200942_bib12","first-page":"OF1","article-title":"TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids","volume":"1","author":"Sun","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.200942_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-01952-w","article-title":"Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2025.200942_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trecan.2022.09.003","article-title":"How cancer cells make and respond to interferon-I","volume":"9","author":"Cheon","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2025.200942_bib15","first-page":"1","article-title":"IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression","volume":"38","author":"Thiem","year":"2019","journal-title":"J.\u00a0Exper. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.200942_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200942_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200942_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.intimp.2018.01.036","article-title":"Interleukin-8 favors pro-inflammatory activity of human monocytes\/macrophages","volume":"56","author":"Meniailo","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omton.2025.200942_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.200942_bib20","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s11033-021-06362-5","article-title":"Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma","volume":"48","author":"Lu","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.omton.2025.200942_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-9896(199701)181:1<14::AID-PATH730>3.0.CO;2-O","article-title":"Distinct mdm2\/p53 expression patterns in liposarcoma subgroups: Implications for different pathogenetic mechanisms","volume":"181","author":"Pilloti","year":"1997","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.omton.2025.200942_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J.\u00a0Clin.\u00a0Oncol."},{"key":"10.1016\/j.omton.2025.200942_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.200942_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2025.200942_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class","volume":"9","author":"Kaufman","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omton.2025.200942_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T\u00a0cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat. Comm."},{"key":"10.1016\/j.omton.2025.200942_bib27","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1245\/s10434-021-11059-x","article-title":"Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors","volume":"29","author":"Cohen","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.omton.2025.200942_bib28","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1200\/JCO.2022.40.16_suppl.9518","article-title":"Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti\u2013PD-1 therapy: MASTERKEY-115","volume":"40","author":"Gastman","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200942_bib29","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1200\/JCO.2023.41.16_suppl.9546","article-title":"Neoadjuvant T-VEC\u00a0+ nivolumab combination therapy for resectable early metastatic (stage IIIB\/C\/D-IV M1a) melanoma with injectable disease: NIVEC trial","volume":"41","author":"Zijlker","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200942_bib30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/sj.gt.3301453","article-title":"A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob","volume":"8","author":"Mizuguchi","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2025.200942_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2007.11.015","article-title":"Development of an adenoviral vector with robust expression driven by p53","volume":"371","author":"Bajgelman","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.omton.2025.200942_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ab.2006.04.032","article-title":"A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers","volume":"354","author":"Peng","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.omton.2025.200942_bib33","first-page":"1","article-title":"Preparation and analysis of monotypic and organotypic tumor spheroids","volume":"1","author":"Domingues","year":"2024","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.omton.2025.200942_bib34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/JLB.3A0718-274RR","article-title":"Lactate secreted by cervical cancer cells modulates macrophage phenotype","volume":"105","author":"Stone","year":"2019","journal-title":"J.\u00a0Leukoc. Biol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:01:45Z","timestamp":1762657305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2950329925000116"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.200942","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.200942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200942"}}